This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
NASA is gearing up this week for a mission to launch a SpaceX Falcon 9 rocket into a near-Earth asteroid in an attempt to move it slightly off its projected course. Thomas Zurbuchen, an associate administrator for the NASA Science Mission Directorate, joined Cheddar's "Opening Bell" to provide some additional details about the Double Asteroid Redirection Test (DART) and explained why it is necessary as a means to protect Earth.
With Thanksgiving two days away, the USDA is reminding hosts of the importance of food safety. Karen Hunter, Food Safety Expert, USDA, joined Cheddar's Opening Bell to discuss the best food handling and leftover tips ahead of the holiday.
Jill and Carlo are a bit delayed today on account of Carlo's internet not working. Better late than never, they discuss what we know about the suspect in the Christmas parade crash, closing arguments in the Arbery killing trial, and more.
If you’ve ever watched a show or movie where a character is unconscious for some reason - drowning, electrocution, stabbed in a knife fight - you probably know what to expect next. Some hero will come perform what looks like cardiopulmonary resuscitation (CPR) for a minute or two, perhaps in slow motion, and definitely with a dramatic musical score. And bing, bang, boom, the unconscious character miraculously comes back to life.
If you’ve ever suspected that this is a gross exaggeration of the efficacy of CPR, well, you’re right. But exactly how wrong Hollywood gets CPR is hilarious at best and downright dangerous at worst.
Countries around the world continue to grapple with rising COVID cases, with Germany confirming case numbers at their highest at any point during the pandemic. German officials say that 48,000 new cases are being reported everyday.
Jill and Carlo cover the developing story out of suburban Milwaukee, where a speeding SUV careened through a Christmas parade. Looters get more brazen in San Francisco, the missing Chinese tennis star resurfaces, and more.
A CDC panel has unanimously endorsed boosters of the Pfizer and Moderna COVID-19 vaccines for all adults. Internal medicine physician Dr. Vivek Cherian joined Cheddar News to weigh in.
Neuroscientist Dr. Bankole Johnson joined Cheddar News to talk about the expectation of boosters for all U.S. adults and what the move would mean in the fight against the pandemic.
Deborah Sass, CO-CEO and Founding Partner of Space Hero, joins ChedHER to discuss how she's creating a global competition to send someone on a 10-day trip to space, her experience in the space industry without a background in STEM, and how she hopes to inspire younger generations of women.
